Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy

The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the appl...

Source: Journal of Hematology and Oncology - November 29, 2019 Category: Hematology Authors: Xiao Han, Yao Wang, Jianshu Wei and Weidong Han Tags: Review Source Type: research